U.S. Human Microbiome Market, By Product (Probiotics, Prebiotics, Diagnostic Tests, Drugs, Supplements, Fecal Microbiota Transplant, and Others), Application (Therapeutic and Diagnostic), Disease (Infectious Disease, Dermatological Disorders, Autoimmune Disorder, Metabolic Disorder, Gastrointestinal Disorders, Cancer, Mental Disorders, Clostridioides Difficile Infection, Primary Hyperoxyureasolution-Phase and Others), Technology (Genomics, Proteomics and Metabolomics), Type (Small Molecule and Biologic), End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Hypermarket/Supermarket, Clinics and Others), Distributor (Direct Tender and Retail Sales) Industry Trends and Forecast to 2029.
U.S. Market Analysis and Insights
Microbiota means the microbial taxa associated with humans and microbiome means "the catalog of these microbes and their genes. The aggregation of all the microbiota reside on or within human tissues and bio fluids along with the corresponding anatomical sites in which they reside, including the skin, mammary glands, seminal fluid, uterus, ovarian follicles, lung, saliva, oral mucosa, conjunctiva, biliary tract and others. The human microbiota consists of the 10-100 trillion symbiotic microbial cells harbored by each person, primarily bacteria in the gut. The human microbiome consists of the genes these cells harbor.
U.S. human microbiome market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyzes that the market is growing with a CAGR of 23.9% in the forecast period of 2022 to 2029 and is expected to reach USD 1,528.06 million by 2029.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (customizable to 2019-2014)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
By Product (Probiotics, Prebiotics, Diagnostic Tests, Drugs, Supplements, Fecal Microbiota Transplant, and Others), Application (Therapeutic and Diagnostic), Disease (Infectious Disease, Dermatological Disorders, Autoimmune Disorder, Metabolic Disorder, Gastrointestinal Disorders, Cancer, Mental Disorders, C. Difficile Infection, Primary Hyperoxyureasolution-Phase and Others), Technology (Genomics, Proteomics and Metabolomics), Type (Small Molecule and Biologic), End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Hypermarket/Supermarket, Clinics and Others), Distributor (Direct Tender and Retail Sales)
|
|
Countries Covered
|
U.S.
|
|
Market Players Covered
|
The major companies which are dealing in the market are 4D pharma plc, Evelo Biosciences, Inc., Viome Life Sciences, Inc., Finch Therapeutics Group, Inc., OptiBiotix HEALTH PLC, BiomX, Sun Genomics, Metabiomics, Osel Inc, Ferring B.V., Merck KGaA, Assembly Biosciences, Inc., Synthetic Biologics, Inc., FlightPath Biosciences, Inc., Vedanta Biosciences, Inc. and Second Genome among others
|
Market Definition
Microbiome is the genetic material of all the microbes - bacteria, fungi, protozoa and viruses - that live on and inside the human body. The number of genes in all the microbes in one person's microbiome is 200 times the number of genes in the human genome. The most widely used method of identification of microbiome analysis is 16s rRNA sequencing. Identification and understanding of these microbiotas have led to the application of these microorganisms in the betterment of human health via various products such as probiotics, prebiotics and other associated drugs.
U.S. Human Microbiome Market Dynamics
Drivers
-
Rising prevalence of lifestyle and chronic diseases
Due to global rise of chronic diseases, there is an increase in the demand for effective treatment products which will increase in upcoming years. Therefore, rising incidences are expected to act as a driver for the growth of the market.
-
Increasing technological advancements in metagenomics and next-generation sequencing
Metagenomics is a novel methodology for studying microorganisms obtained from specific environments through functional gene screening. It is focused on microbial diversity, genetic relationships, functional activities and relationships with the environment, whereas sequencing technology is used for the diagnosis or the treatment of disease evolved from shot-gun sequencing, high-throughput, next-generation sequencing and third-generation sequencing. Next generation and third generation sequencing shows the advantage of rapid detection of microorganisms.
Furthermore, improved technology advancement, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will drive the growth of the market.
So due to increase in technology advancement in sequencing it will drive the market.
Opportunities
-
Rise in healthcare expenditure
Products associated with the human microbiome, such as probiotics, prebiotics, drugs and supplements, are costly. A normal low-income and middle-income family cannot adequately treat gut-related diseases properly. The government is focusing on increasing healthcare expenditure to access available treatments and new products.
Also, the strategic initiatives by key players and rise in healthcare expenditure will provide structural integrity and future opportunities for the market in the forecast period of 2022-2029.
Restraints/Challenges
- Lack of skilled professionals
However, lack of technology expertise and barriers proving the causal link between dysbiosis and diseases will impede the growth rate of Human Microbiome Market. Additionally, difficulty in specific identification and stringent rules and regulations will further challenge the market in the forecast period mentioned above.
Post COVID-19 Impact on U.S. Human Microbiome Market
COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to healthcare facilities for routine treatment and medication administration will further affect the market. Social isolation increases stress, despair and social support, all of which may cause a reduction in medication adherence during the pandemic.
Recent Development
- In March 2020, Optibiotix Health PLC had done LPLDL human intervention study from ProBiotix Health which highlighted promising findings on cholesterol reduction
The U.S. Human Microbiome Market Scope
The U.S. human microbiome market is segmented into product, application, technology, type, disease, end users and distributors. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product
- Probiotics
- Prebiotics
- Diagnostic Tests
- Drugs
- Supplements
- Fecal Microbiota Transplant
- Others
On the basis of product, the market is segmented into probiotics, prebiotics, diagnostic tests, drugs, supplements, fecal microbiota transplant and others.
Application
- Therapeutic
- Diagnostic
On the basis of application, the market is segmented into therapeutic and diagnostic.
Disease
- Infectious Disease
- Dermatological Disorders
- Autoimmune Disorder
- Metabolic Disorder
- Gastrointestinal Disorders
- Cancer
- Mental Disorders
- C. Difficile Infection
- Primary Hyperoxyureasolution-Phase
- Others
On the basis of disease, the market is segmented into infectious disease, dermatological disorders, autoimmune disorder, metabolic disorder, gastrointestinal disorders, cancer, mental disorders, C. difficile infection, primary hyperoxyureasolution-phase and others.
Technology
- Genomics
- Proteomics
- Metabolomics
On the basis of technology, the market is segmented into genomics, proteomics and metabolomics.
Type
- Small Molecule
- Biologic
On the basis of type, the market is segmented into small molecule and biologic.
End User
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Hypermarket/Supermarket
- Clinics
- Others
On the basis of end user, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, hypermarket/supermarket, clinics and others
Distributor
-
Direct Tender
-
Retail Sales
On the basis of distributor, the market is segmented into direct tender and retail sales.
U.S. Human Microbiome Market Regional Analysis/Insights
The U.S. human microbiome market is analyzed and market size insights and trends are provided by product, application, disease, technology, type, end users and distributor as referenced above.
The country covered in the U.S. human microbiome market report is the U.S.
U.S. human microbiome market is dominating due to the increasing healthcare expenditure in the U.S.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Human Microbiome Market Share Analysis
The U.S. human microbiome market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth and application dominance. The above data points provided are only related to the companies' focus on the market.
Some of the major players operating in the U.S. market are 4D pharma plc, Evelo Biosciences, Inc., Viome Life Sciences, Inc., Finch Therapeutics Group, Inc., OptiBiotix HEALTH PLC, BiomX, Sun Genomics, Metabiomics, Osel Inc., Ferring B.V., Merck KGaA, Assembly Biosciences, Inc., Synthetic Biologics, Inc., FlightPath Biosciences, Inc., Vedanta Biosciences, Inc. and Second Genome among others.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, U.S. Vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
SKU-